Abstract
Conventional chemotherapies for medulloblastoma are restricted to only proliferative population leaving the cancer stem cells unscathed. This shortcoming of the traditional therapies is attributed to the relapse and metastasis of the cancer. The current research is entirely focused on the screening of therapeutic agents that can restrict and target the self-renewal potential of the cancer stem cells. The advances in drug screening strategies have led to high-throughput screening which provide a robust and expeditious platform to screen potential compounds against cancer stem cells. In this book chapter, we describe two in vitro assays that are routinely used to measure the cell killing and antiāself-renewal activity of the compounds against the cancer stem cells. Combining these assays with high-throughput screening offers a rapid, reliable, and inexpensive approach to screen potential compounds against cancer stem cells and to overcome the limitation of conventional chemotherapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Warmuth-Metz M, Blashofer S, von Bueren AO et al (2011) Recurrence in childhood medulloblastoma. J Neuro-Oncol 103:705ā711
Manoranjan B, Venugopal C, McFarlane N et al (2012) Medulloblastoma stem cells: where development and cancer cross pathways. Pediatr Res 71:516ā522
Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396ā401
Alison MR, Lin W-R, Lim SML, Nicholson LJ (2012) Cancer stem cells: in the line of fire. Cancer Treat Rev 38:589ā598
Read T-A, Fogarty MP, Markant SL et al (2009) Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15:135ā147
Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18:17ā26
Kool M, Koster J, Bunt J et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088
Northcott PA, Korshunov A, Witt H et al (2011) medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408ā1414
Pomeroy SL, Tamayo P, Gaasenbeek M et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436ā442
Thompson MC, Fuller C, Hogg TL et al (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924ā1931
Clifford SC, Lusher ME, Lindsey JC et al (2006) Wnt/wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub-group of medulloblastomas associated with a favourable prognosis. Cell Cycle 5:2666ā2670
Ellison DW, Onilude OE, Lindsey JC et al (2005) Ī²-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom childrenās cancer study group brain tumour committee. J Clin Oncol 23:7951ā7957
Fattet S, Haberler C, Legoix P et al (2009) Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218:86ā94
Broach JR, Thorner J (1996) High-throughput screening for drug discovery. Nature 384:14ā14
Acknowledgments
IIT Mandi is acknowledged for providing laboratory facilities. Neha Garg is supported by DST Ramanujan grant, India (SB/S2/RJN-072/2015), (ECR/2017/00092) and the seed grant under Institute of Eminence Scheme (IOE), BHU. Ashutosh Singh gratefully acknowledges UGC, India, for a senior research fellowship.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Singh, A., Garg, N. (2022). Drug Screening Assays on Medulloblastoma Stem Cells Using Compound Libraries. In: Dey, A., Malhotra, A., Garg, N. (eds) Medulloblastoma. Methods in Molecular Biology, vol 2423. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1952-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1952-0_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1951-3
Online ISBN: 978-1-0716-1952-0
eBook Packages: Springer Protocols